Hydromorphon Al

Hydromorphone, the active ingredient in Hydromorphon Al, is an opioid analgesic presented as an unknown strength oral tablet for oral use. It treats moderate to severe pain, including postoperative and cancer‑related pain, in adult patients.

GNH USA supplies Hydromorphon Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphon Al, an opioid analgesic, is used to manage pain conditions where strong opioid therapy is indicated.

- Moderate to severe pain: provides effective relief for acute or chronic pain that is not controlled by non‑opioid analgesics. - Postoperative pain: helps control pain following surgical procedures, facilitating recovery. - Cancer pain: alleviates persistent pain associated with malignant disease and its treatment.

Hydromorphon Al may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Dependence or addiction

When prescribing Hydromorphon Al, clinicians should observe several safety measures to minimize risk.

- Assess pain severity: confirm that opioid therapy is appropriate for the patient’s pain level. - Monitor respiratory function: observe for signs of respiratory depression, especially after dose initiation or escalation. - Evaluate hepatic and renal function: adjust dosing in patients with impaired liver or kidney function. - Avoid use in acute asthma or severe respiratory compromise: risk of bronchospasm and respiratory failure. - Use caution with other CNS depressants: concurrent benzodiazepines or alcohol may enhance sedation and respiratory effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Hydromorphon Al can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation or respiratory depression. - MAO inhibitors: risk of severe hypotension and serotonin syndrome. - Other opioids: additive respiratory depression and sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may increase hydromorphone plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antidepressants (SSRIs/SNRIs): potential for serotonin syndrome when combined with MAO inhibitors.